Sheehy Douglas T. 4
4 · Aimmune Therapeutics, Inc. · Filed Dec 30, 2019
Insider Transaction Report
Form 4
Sheehy Douglas T.
See Remarks
Transactions
- Exercise/Conversion
Common Stock, $0.0001 par value
2019-12-26$12.95/sh+10,000$129,500→ 55,668 total - Sale
Common Stock, $0.0001 par value
2019-12-26$33.03/sh−10,000$330,322→ 45,668 total - Exercise/Conversion
Stock Option (right to buy)
2019-12-26−10,000→ 53,649 totalExercise: $12.95Exp: 2026-04-29→ Common Stock (10,000 underlying)
Footnotes (5)
- [F1]The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person.
- [F2]Includes 29,617 restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
- [F3]Includes 12,500 restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
- [F4]Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $33.00 to $33.15 per share. Information on the actual numbers of shares sold at each sale price can be obtain from Issuer upon request.
- [F5]The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on April 4, 2017 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to Reporting Person's continued service relationship with Issuer on each such vesting date.